Dermatopontin Regulates Fibrin Formation and Its Biological Activity  by Wu, Weimin et al.
Dermatopontin Regulates Fibrin Formation and its
Biological Activity
Weimin Wu1, Osamu Okamoto2, Aiko Kato1, Noritaka Matsuo3, Motoyoshi Nomizu4, Hidekatsu Yoshioka3
and Sakuhei Fujiwara2
Dermatopontin (DP) is a small extracellular matrix component in the dermis. Fibrin is a major component of a
provisional matrix that is formed just after wounding. Previously, we found that DP was present in the provisional
matrix, and it interacted with fibrin. Here, we examined the role of DP on fibrin function. DP interacted with both
the fibrin monomer and fibrils, and was incorporated into the fibrils during fibrin formation. A DP sequence,
PHGQVVVAVRS, was identified as a fibrin-binding site, and a globular D domain of fibrin was the binding site for
DP. DP accelerated fibrin fibril formation into structurally modified fibrils. Fibrin fibrils formed in the presence of
DP enhanced both endothelial cell attachment and cell spreading. The attached cells developed a more
organized cytoskeleton when compared with those that attached to fibrin fibrils only. The main receptor for cell
adhesion was identified as avb3 integrin, and a cooperating receptor was a b1-containing integrin species,
probably a5b1 integrin. These results indicate that DP can modify certain biological functions of fibrin, and thus a
another function of this extracellular matrix protein was revealed. In addition, the fibrin–DP complex might
become useful for developing an improved artificial matrix for improving wound healing.
Journal of Investigative Dermatology (2014) 134, 256–263; doi:10.1038/jid.2013.305; published online 15 August 2013
INTRODUCTION
Dermatopontin (DP) is a small acidic extracellular matrix
protein with a molecular weight of 22 kDa (Okamoto and
Fujiwara 2006; Okamoto et al., 2011). It is an enriched protein
within a population of small proteins having molecular weight
o40–50 kDa in the dermis. In spite of its abundance in
the dermis, knowledge about DP is limited. DP interacts
with decorin, an abundant proteoglycan in the dermis
(Lewandowska et al., 1991; Okamoto et al., 1996), and it
accelerates collagen fibrillogenesis (MacBeath et al., 1993).
DP-knockout mice demonstrate an Ehlers–Danlos syndrome
phenotype, showing skin fragility, disturbed lateral arrange-
ment of collagen microfibrils, and a modified arrangement of
corneal collagen (Takeda et al., 2002; Cooper et al., 2006).
Apart from the structural aspects above, functional analyses
of DP are very limited, but we previously found that DP is a
potent cell adhesion protein for keratinocytes (Okamoto et al.,
2010). In addition, we have found that DP interacts with
transforming growth factor-b1, and that DP expression is also
induced by this growth factor (Kuroda et al., 1999; Okamoto
et al., 1999). DP was found to be overexpressed in the
myocardial infarct zone; its expression profile correlated
with collagen (Takemoto et al., 2002). These findings
suggest that DP affects epidermal cells and promotes wound
healing of the skin and other tissues. Recently, we reported
that DP is present in the provisional matrix mainly composed
of fibrin and fibronectin, and in the serum (Kato et al., 2011).
We showed that DP interacts with both fibrin and fibronectin;
it induces the formation of fibronectin fibrils by activating it.
The activated fibronectin enhanced fibroblast cell adhesion.
These findings indicate that DP functions not only in the
dermis but also plays important roles in an early phase of
wound healing.
Fibrin is the major protein in the provisional matrix (Singer
and Clark, 1999; Diegelmann and Evans, 2004). It is formed
from fibrinogen by thrombin cleavage of fibrinopeptides A and
B. Fibrinogen is a dimeric molecule composed of three paired
chains, namely Aa, Bb, and g chains, and the amino termini
of these chains are connected, forming an E domain, and the
carboxyl part of each monomer assembles and forms two
D domains (Mosesson, 2005) (schematically explained in
Figure 1). Once the vessels are damaged, circulating fibrino-
gen is locally converted to fibrin, and it forms a provisional
matrix together with fibronectin and other components. Then,
platelets, leukocytes, endothelial cells, and fibroblasts attach
to the provisional matrix, leading to the formation of new
vessels and granulation tissue.
ORIGINAL ARTICLE
1Department of Plastic Surgery, Faculty of Medicine, Oita University, Oita,
Japan; 2Department of Dermatology, Faculty of Medicine, Oita University,
Oita, Japan; 3Department of Biochemistry, Faculty of Medicine, Oita
University, Oita, Japan and 4Department of Laboratory of Clinical
Biochemistry, School of Pharmacy, Tokyo University of Pharmacy and Life
Sciences, Tokyo, Japan
Correspondence: Osamu Okamoto, Department of Dermatology, Faculty of
Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, Yufu-shi, Oita 879
5593, Japan. E-mail: ookamoto@oita-u.ac.jp
Received 4 January 2013; revised 7 June 2013; accepted 14 June 2013;
accepted article preview online 22 July 2013; published online 15 August
2013
Abbreviations: DP, dermatopontin; HUVEC, human umbilical vein endothelial
cell
256 Journal of Investigative Dermatology (2014), Volume 134 & 2014 The Society for Investigative Dermatology
During examination of the DP–fibronectin–fibrin inter-
action, we found that the interaction between DP and fibrin
was potent. Therefore, we closely examined the DP–fibrin
interaction and found its another function. We also examined
the effects of DP on the biological activity of the fibrin, and
based on the effects, we discuss the function of DP and a
possible therapeutic use.
RESULTS
Identification of fibrin binding sites on DP
DP bound to immobilized fibrin and to fibrinogen in a
dose-dependent manner (Figure 2a). When we examined the
inhibition of DP binding to the immobilized fibrin by synthetic
DP peptides, only DP-4 peptide specifically inhibited the
interaction (Figure 2b). In addition, a biotinylated DP-4
peptide interacted with fibrin, whereas a biotinylated DP-4S
peptide, a scrambled DP-4 peptide, did not bind (Figure 2c).
These results indicate that the DP-4 peptide directly interacts
with fibrin and the activity is sequence specific.
Next, the D and E domains of fibrinogen (Figure 1) were
immobilized and their interaction with DP was examined.
DP interacted with the D domain as well as fibrinogen but not
with the E domain (Figure 2d). Similarly, the DP-4 peptide
bound to the immobilized D domain (Figure 2e) but, as
expected, the DP-4S peptide did not interact with the D
domain (Figure 2e). In addition, the DP-4 peptide did not bind
to the immobilized E domain (data not shown). Furthermore,
the interaction between DP and the D domain was inhibited
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Figure 1. Schematic structures of fibrinogen, fibrin, and fibrin fibrils.
(a) Fibrinogen molecule. Circles represent D domains; a central rectangle
represents an E domain. Small rectangles A and ovals B indicate
fibrinopeptides A and B, respectively. The a, b, and g represent the
a, b, and g chains of fibrinogen. aC indicates a carboxyl terminal part of
the a chain. (b) Fibrin monomer. EA and EB represent active sites of the
a and b chains exposed by cleavage of fibrinopeptides A and B. Rectangles
Db indicate active sites that bind with EB domains. (c) Fibrin fibrils.
Covalent bonds between two g chains are indicated by thick black lines,
by which g chain dimers are formed. Each protofibril is surrounded by a
rectangle.
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Figure 2. Identification of binding site in dermatopontin (DP). (a) A solid-phase assay of interaction between DP and fibrin (J) and fibrinogen (m).
DP at indicated concentrations was added. (b) Inhibition of the interaction between DP and fibrin by synthetic DP peptides. (c) Interaction between DP-4
peptide and fibrin. Biotinylated DP-4 peptide (J) was added. Biotinylated DP-4S peptide (m) was used as a control. (d) Interaction between DP and the D and E
domains of fibrinogen. (e) Interaction between DP-4 peptide and the D domain. (f) Inhibition of interaction between DP and D domain by DP-4 peptide.
DP-4S peptide was used as a control. Data are presented as mean±SD, *Po0.05.
W Wu et al.
Dermatopontin Interaction with Fibrin
www.jidonline.org 257
by the DP-4 peptide but not by the DP-4S peptide (Figure 2f).
These results suggest that DP interacted with the fibrinogen D
domain through the DP-4 sequence.
DP affects fibrin formation
Next, we examined the effect of DP on fibrin fibril formation.
When fibrinogen is incubated with thrombin, the resulting
fibrin molecules polymerize and the turbidity of the solution
increases (Wolberg, 2007). When fibrinogen alone was
incubated with thrombin, the turbidity increased after a short
lag time and then reached a plateau at B30 minutes
(Figure 3a). In the presence of DP, the final turbidity became
greater in proportion to the DP concentration (Figure 3a). In
contrast, when DP and thrombin, or DP and fibrinogen,
were coincubated, no apparent turbidity change was observed
(data not shown). DP did not influence the thrombin activity
as assessed by a chromogenic substrate S-2238 (data not
shown). Crosslink formation, as assessed by the g-chain
dimer (Figure 1), was not affected by DP (data not shown).
These data indicate that DP directly accelerates fibrin fibril
formation.
Next, we examined whether DP is incorporated into
fibrin fibrils. Fibrinogen was coincubated with DP and
thrombin, and the resulting insoluble fibrils were separated
by centrifugation. Figure 3b shows a clear 22-kDa band in the
pellet, and the band was not seen in that formed in the
absence of DP. The identity of the band as DP was confirmed
by western blotting (Figure 3b). Thus, it was proven that DP
not only interacts with preformed fibrin monomers, but also is
incorporated into the fibrin fibrils.
Because DP was incorporated in fibrin fibrils, the inter-
action between fibrin fibrils and DP was examined. When DP
was incubated with preformed fibrin fibrils in solution, DP
coprecipitated with the fibrin fibrils after centrifugation
(Figure 3c, lane 2). Coprecipitated BSA was also present but
in a trace amount (Figure 3c, lane 4). When preformed fibrin
fibrils were immobilized on a solid phase, DP also showed a
clear interaction (Figure 3d). Thus, DP interacts with fibrino-
gen, fibrin monomer, and fibrin fibrils, and these results
support the incorporation of DP in fibrin fibrils as shown in
Figure 3b.
DP affects the structure of fibrin fibrils
The increase in the turbidity by DP during fibrin fibril
formation was reminiscent of certain structural changes of the
fibrin fibrils. Therefore, we compared the ultrastructure of
fibrin fibrils formed in the presence and absence of DP.
Fibrin alone formed fibrils with diameters of B50 nm
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Figure 3. Effects of dermatopontin (DP) on fibrin fibril formation. (a) Fibrin formation assay. Fibrin was formed with DP, and the absorbance at 405 nm
was monitored. Coincubated DP concentrations are shown in the graph. (b) DP is incorporated in the newly formed fibrin fibrils. The supernate and pellet
of the fibrin fibril suspension made as above were analyzed. Coomassie stain is shown in the upper panel, and detection of DP by western blotting is shown
in the lower panel. (c) DP interacts with preformed fibrin fibrils. Liquid-phase assay. Fibrin fibrils were preformed and DP (lanes 1 and 2) or BSA (lanes 3 and 4)
were incubated and were analyzed. BSA was analyzed with a conventional 10% gel in nonreducing conditions. (d) Solid-phase assay. The left lane
indicates DP interaction with fibrin fibrils and the right lane is the background.
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(Figure 4a and b). Thinner fibrils of several nm in diameter
surrounded the thick fibrils and often merged into them
(Figure 4b). In contrast, fibrin in the presence of DP formed
fibrils thicker in diameter (50–100 nm; Figure 4c and d).
Furthermore, there were fewer observable thinner fibrils
around the thicker fibrils, and these thicker fibrils appeared
more solid. No fundamental difference of fibrinolysis of these
fibrin fibrils was seen (data not shown).
DP enhances adhesion and spreading of HUVECs on fibrin
Next, we examined the effect of DP on the biological activity
of fibrin. Human umbilical vein endothelial cell (HUVEC)
adhesion to fibrin was examined (Figure 5). HUVECs adhered
only weakly to DP when immobilized solely at high concen-
tration (data not shown), and apparent adhesion was not seen
with the concentrations used in this experiment (Figure 5a).
On the other hand, HUVECs adhered to fibrin in a dose-
dependent manner (data not shown). When HUVECs were
inoculated on fibrin made in the presence of DP, the number
of attached cells was enhanced in a dose-dependent manner
(Figure 5a). The enhancement reached a plateau at
B2.5mg ml 1 of DP. Accordingly, cell spreading was clearly
enhanced as a function of the coincubated DP concentrations
(Figure 5b and c). The enhancement of cell adhesion was
strongly inhibited by anti-avb3 integrin antibody and weakly
by anti-av-subunit antibody (Figure 5d). A complete inhibition
was achieved with a mixture of anti-avb3 and b1-subunit
antibodies. An almost identical inhibition profile was obtained
in the cell adhesion assay to fibrin only (data not shown).
These data suggest that structurally modified fibrin fibrils by
DP have an enhanced cell adhesion activity, and that the main
cellular receptor is an avb3 integrin.
Fibrin–DP complex supports HUVEC cytoskeletal organization
Then, we investigated the effect of DP on the cytoskeletal
formation of HUVECs adhering to fibrin. HUVECs adhered to
Figure 4. Morphological change of fibrin fibrils by dermatopontin (DP).
(a, b) Fibrin fibrils formed in the absence of DP. (c, d) Those formed in
the presence of 200mg ml1 of DP. Scale bar¼ 2mm (for a, c; original
magnification  10,000) and 200 nm (for b, d; original magnification
100,000).
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Figure 5. Effect of dermatopontin (DP) on human umbilical vein endothelial cell (HUVEC) adhesion to fibrin. (a) Fibrin fibrils were formed in the presence
of DP and HUVEC adhesion was quantified. A horizontal line indicates DP concentrations. Data are presented as mean±SD. (b) Morphologies of the
HUVECs adhering to the fibrin fibrils formed with DP. Scale bars¼ 50mm. (c) Quantification of cell spreading. The area of each adhered cell was measured,
and histograms were made. Classification of each bar is explained at the bottom. Population bars that significantly differed from those in the control
experiment (‘‘DP 0’’) are marked by asterisks. *Po0.05. (d) Inhibition of cell adhesion to fibrin–DP substrate by antibodies. Antibodies are indicated in the
horizontal line. *Po0.05. PBS, phosphate-buffered saline; VE-cad, vascular endothelial–cadherin.
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immobilized fibrin (Figure 6a), but the spreading was poor
as visualized by crystal violet stain, and a fluorescent
analysis demonstrated limited cytoskeleton formation
(Figure 6g–i). DP alone promoted weak cell adhesion, and
minimal cell spreading (Figure 6b). On the other hand,
spreading of the cells that adhered to the fibrin–DP complex
was enhanced (Figure 6c), as was observed in the 96-well
plate. Similarly, the formation of the actin fibers and accumu-
lation of vinculin in these cells were enhanced (Figure 6d–f)
when compared with those formed on immobilized fibrin
alone (Figure 6g–i).
DISCUSSION
Previously, we reported that DP interacts with fibrin, and the
interaction of DP with fibrinogen was weaker than that with
fibrin (Kato et al., 2011). However, in this study, we found that
DP also interacts with fibrinogen at a quite similar level as
with fibrin. In this study, the results are highly reproducible
and the reason why the discrepancy occurred might be
because of poor optimization of the reaction conditions of
the previous DP–fibrinogen interaction experiment.
These data indicate that DP interacts not only with the fibrin
monomer but also with the higher-order structure of fibrin
fibrils. We showed that the D domain of fibrin binds to DP,
but the isolated a, b, and g chains of D domain did not
interact with DP (data not shown). Therefore, DP recognized
a certain three-dimensional structure in the D domain. On
the other hand, a DP-4 peptide was identified as an interaction
site with the D domain. The DP-4 peptide has also been
indentified as a syndecan-binding site in our previous study
(Okamoto et al., 2010). The DP-4 peptide has multiple
functions for cell adhesion and for interaction between the
extracellular matrix proteins. However, it still remains
unknown if the DP-4 peptide can reproduce the major
functions of DP. If DP-4 peptide functions like DP, it would
suggest an attractive possibility for controlling certain
biological events by this peptide.
Newly generated fibrin monomers first form linear proto-
fibrils. Then the fibrils are laterally connected, making a
network recognized as the fibrin clot (Mosesson, 2005).
It is believed that the lateral association of the protofibrils
reflects the turbidity change (Figure 1) (Wolberg, 2007).
Therefore, the DP-induced turbidity increase during fibrin
fibril formation indicates that DP accelerates the lateral
association of fibrin protofibrils. This observation was
supported by the ultrastructure of the fibrin fibrils formed in
the presence of DP, where the diameters of the fibrils are
increased. The lateral association of the protofibrils is
generally believed to occur via the interaction of an EB site
of b chain with a Db site of the D domain of another fibrin
monomer (Figure 1) (Medved et al., 1993; Everse et al., 1998;
Betts et al., 2006). As DP interacts with the D domain, it is
feasible that DP affects the interaction between EB and Db
sites.
Because DP remained in the newly formed fibrin fibrils, it is
likely that DP functions as a connecting molecule between
Figure 6. Appearance of the cytoskeleton of human umbilical vein endothelial cells (HUVECs) adhering to fibrin–dermatopontin (DP) matrix. (a–c) Crystal
violet stains of HUVECs that adhered to (a) fibrin fibrils alone, (b) DP alone, and (c) fibrin fibrils made with DP, respectively. (d–f) HUVECs that adhered
to the fibrin fibrils made in the presence of DP. (g–i) HUVECs that adhered to the fibrin fibrils alone. (d, g) Phalloidin staining, (e, h) vinculin staining,
and (f, i) merged images. Inserts in d and g are close-up views of the cytoskeleton. Bar¼50mm.
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adjacent fibrin molecules. The resulting structural change of
fibrin fibrils would enhance both HUVEC adhesion and
spreading. Several cell surface receptors have been identified
for adhesion to fibrin (Sakura et al., 1997; Bach et al., 1998).
As expected, avb3 integrin was identified as a main receptor
involved in the adhesion of HUVECs to the fibrin–DP com-
plex. In this study, we also confirmed that the avb3 integrin is
a main receptor for adhesion to fibrin (data not shown). Thus,
within the fibrin–DP complex, the cells adhere to fibrin. In
addition, b1-containing integrin cooperated with avb3 integrin
for cell adhesion. As a5b1 integrin has been identified as a
fibrinogen receptor (Suehiro et al., 1997), this integrin species
is supposed to contribute to the cooperation. The receptors
interact with fibrin at the aC region of the Aa chain that
extends from a D domain (Figure 1a and b) (Cheresh et al.,
1989; Felding-Habermann et al., 1992), and hence it is
supposed that after binding of DP with the D domain, the
conformation of the adjacent aC region changes so that it is
more accessible for the cells.
Fibrin serves as a scaffold for endothelial cells in the initial
phase of the wound healing for allowing angiogenesis
(Lamalice et al., 2007). The fibrin structure changes depen-
ding on diseases or on chemical conditions, and its function
can be modified (Laurens et al., 2006). Accordingly in this
study, DP promoted the formation of thicker fibrin fibrils and
enhanced cell adhesion and spreading. In a previous report,
thick fibrin fibrils suppressed capillary tube formation (Nehls
and Herrmann, 1996). On the other hand, in another report,
the ingrowth of tubular structures is accelerated by thick
fibrin fibrils (Collen et al., 1998). Hence the behavior of the
endothelial cells on the structurally modified fibrin fibrils
may vary depending on the assay used. Thus, at present, the
fate of the enhanced cell adhesion and spreading by a simple
combination of DP and fibrin remains uncertain. Further
investigation of the modification of the cell behavior by
fibrin–DP complex will be required.
In this study, DP was used in a concentration range
between several mg ml1 and several hundred mg ml1.
Approximately 50 mg of DP can be purified from 1 kg of the
dermis (Okamoto et al, 2011), and hence the physiological DP
concentration in the dermis can be estimated to be B50mg
per g wet weight. The DP concentration in the fibrin
provisional matrix has not been determined, but considering
from its concentration in the surrounding dermis, the concen-
tration would be much less than the dermal level. Thus, in
some experiments in this study, the DP concentrations
exceeded these physiological concentrations. Therefore, the
observed effects of DP on fibrin fibril formation and, possibly,
cell adhesion may not always reflect the in vivo state.
The effects of DP on fibrin functions observed in this study
imply a possibility that certain biological events, such as
wound healing, are regulated by externally adding DP-loaded
artificial fibrin provisional matrix. The authentic provisional
matrix does not comprise fibrin only, but it contains fibro-
nectin as a major nonfibrin component (Clark et al., 1982). In
our previous report, DP was found to activate fibronectin (Kato
et al., 2011), and the activated fibronectin demonstrated a
pronounced cell adhesion activity (Morla et al., 1994). Taking
fibronectin activation and the enhancement of cell adhesion
to fibrin into account, DP is a likely factor for positively
regulating wound healing by combining with these provisional
matrix components. By adjusting the composition of these
components, it is expected that an improved artificial
provisional matrix for controlling wound healing might be
developed in the future.
MATERIALS AND METHODS
Materials
DP was purified and an anti-DP carboxyl terminal peptide antibody
was produced as reported previously (Okamoto et al., 1996).
HUVECs were purchased from DS Pharma Biomedical (Osaka,
Japan). Bovine fibrinogen and human D and E fragments were
purchased from Merck-Calbiochem Japan (Tokyo, Japan). Function-
blocking anti-integrin subunit antibodies (LM609 for integrin avb3,
P1D6 for a5, and 6S6 for b1) were from Chemicon (Temecula, CA),
and BV9 for vascular endothelial–cadherin was from Hycult Biotech
(Plymouth Meeting, PA). An anti-vinculin antibody was from Enzo
Life Sciences International (Plymouth Meeting, PA), and an Alexa
Fluor 594–labeled anti-mouse IgG antibody was from Invitrogen
(Carlsbad, CA). Overlapping peptides of DP were synthesized as
described previously (Okamoto et al., 2010). The nomenclature and
the amino acid sequences are the same as those described in the
report.
Solid-phase assay for protein interaction
The experiment was done according to a protocol described pre-
viously (Kato et al., 2011). In brief, fibrinogen, D and E domains were
coated in wells of a 96-well plate at 10mg ml 1. When necessary, the
fibrinogen was converted to fibrin by thrombin. This was recognized
as fibrin monomer. After blocking, DP was added to the wells and
was incubated overnight. Bound DP was probed with anti-DP
antibody. For assessing the interaction between fibrin fibrils and
DP, fibrinogen solution at 5mg ml 1 in 50 mM HEPES buffer
(0.14 M NaCl and 20 mM CaCl2, pH 7.5) was mixed with thrombin
at 1 U ml 1, the mixtures were incubated overnight at room
temperature, and the generated fibrin fibrils were immobilized.
The DP concentration was 1mg ml 1.
Biotinylation of DP-4 peptide
DP-4 peptide truncated by one amino-terminal proline
(HGQVVVAVRS) and a scrambled peptide DP-4S (VRVHVPVQGSA)
were dissolved in 0.1 M phosphate buffer (0.15 M NaCl, pH 8.0).
Sulfo-NHS-LC-biotin was added and the mixtures were incubated for
3 hours at 4 1C. The reaction was terminated by an addition of Tris/
HCl, pH 7.5, at a final concentration of 50 mM and the mixtures were
incubated for 1 hour at 4 1C. The mixture was placed on a Biogel P4
(Bio-Rad, Hercules, CA) column equilibrated with 0.1% trifluoro-
acetic acid/30% acetonitrile. Void fractions were collected and were
lyophilized and the samples were dissolved in phosphate-buffered
saline. The biotinylated truncated DP peptide is termed biotinylated
DP-4 peptide in this study.
Fibrin formation assay
Fibrinogen dissolved in HEPES buffer was added to wells of a 96-well
plate, and a mixture of thrombin and DP was added to the wells.
The turbidity change of the solution was monitored at 405 nm. The
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final concentration of fibrinogen and thrombin was 1.6 mg ml 1 and
1 U ml 1, respectively. An aliquot of the samples was taken and
analyzed by conventional 10% gel, or 12% T, 0.3% C tricine gel in
reducing conditions (Scha¨gger and von Jagow, 1987).
Liquid-phase assay for DP–fibrin fibril interaction
Fibrin fibrils were formed, and then Tween-20 was added at a final
concentration of 0.05%. DP or BSA was added and incubated
overnight. The initial concentration of fibrinogen was 800mg ml 1,
and of DP and BSA were 100mg ml 1. After centrifugation, the pellet
was washed, and analyzed by SDS-PAGE.
For detection of DP, the electrophoresed proteins were western
blotted to polyvinylidene fluoride membranes, followed by incuba-
tion with an anti-DP rabbit antibody, then with a horseradish
peroxidase-conjugated anti-rabbit IgG antibody. Images were visua-
lized using an enzyme chemiluminescence reagent.
Electron microscopy
After the fibrin formation assay, the samples were transferred to
microtubes and were centrifuged, and the pellet was fixed with 2%
formaldehyde (2.5% glutaraldehyde), 50 mM cacodylate buffer, pH
7.4, containing 3 mM CaCl2. The samples were embedded in Epon
resin, sliced as 1mm sections, were stained with 1% OsO4 and 1%
tannic acid, dehydrated, dried, and coated with OsO4. All the
observations and photographs were performed at an acceleration
voltage of 15 kV.
Cell adhesion assay
HUVECs were cultured in KJB-210 medium at 37 1C. The cell
adhesion assay was performed according to the protocol described
previously (Kato et al., 2011). Briefly, 2.5mg ml 1 of fibrinogen was
incubated with 1 U ml 1 of thrombin in the presence and absence of
DP for 2 hours, and the samples were coated in the wells. HUVECs
suspended at 30,000 cells per 100ml in DMEM were inoculated and
cell adhesion was assessed after 1 hour. The dried stained cells in the
center of the wells were photographed and the cell surface areas were
calculated. Finally, the dye was eluted and an absorbance at 595 nm
was determined.
For an assessment of receptors for cell adhesion, fibrin was made
using 2.5mg ml 1 of fibrinogen and 5mg ml 1 of DP, and the cell
suspension was incubated with function-blocking antibodies at
10mg ml 1.
Cytoskeletal staining
A total volume of 20mg ml 1 of fibrinogen was incubated with
1 U ml 1 of thrombin in the absence or presence of 40mg ml 1 of DP
for 2 hours. Then, 10ml of samples was coated on glass plates (Dako
Japan, Kyoto, Japan) overnight. After blocking with 1% BSA, HUVECs
were suspended in DMEM at a density of 10,000 cells per 10ml, and
the cells were inoculated. After adhesion for 1 hour at 37 1C, the
attached cells were fixed with 3.7% formaldehyde, dehydrated in
acetone, followed by rehydration in phosphate-buffered saline, and
permeabilized with 0.1% Triton X-100. Actin was detected using
FITC-conjugated phalloidin. Vinculin was detected by anti-vinculin
antibody followed by incubation with Alexa Fluor 594–labeled
anti-mouse IgG antibody. Finally, the images were acquired using
a confocal laser scanning microscopy, PASCAL (Carl Zeiss,
Oberkochen, Germany).
Statistical analyses
A statistical assessment for protein interaction was done using t-test,
and a P-value of o0.05 was recognized as significant. The relevant
experiments were repeated more than three times in triplicate. For an
assessment of cell spreading, surface areas of the attached cells were
measured. The measured areas were classified into four populations
as shown in Figure 5. Then, a population with the smallest cell
surface area and another population was selected from both control
and experimental groups, respectively, and a 2 2 w2 test was
performed.
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